Selective activation of estrogen receptor-β transcriptional pathways by an herbal extract

Endocrinology

Volumn 148, Issue 2, 2007, Pages 538-547

  Cvoro, Aleksandra ^a,b   Paruthiyil, Sreenivasan ^a,b   Jones, Jeremy O ^b   Tzagarakis Foster, Christina ^a,b   Clegg, Nicola J ^a,b   Tatomer, Deirdre ^a,b   Medina, Roanna T ^a,b   Tagliaferri, Mary ^c   Schaufele, Fred ^b   Scanlan, Thomas S ^a,b   Diamond, Marc I ^b   Cohen, Isaac ^c   Leitman, Dale C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Bionovo Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR BETA; HERBACEOUS AGENT; PROTEINASE;

ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ESTROGEN ACTIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE ACTIVATION; HOT FLUSH; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; XENOGRAFT;

ANEMARRHENA; ANIMALS; BREAST NEOPLASMS; CARCINOGENS; CELL DIVISION; CELL LINE; DIETHYLSTILBESTROL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS; FEMALE; HUMANS; MICE; MICE, NUDE; MOLECULAR CONFORMATION; NEOPLASM TRANSPLANTATION; ORGAN SIZE; PLANT EXTRACTS; RESPONSE ELEMENTS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; UTERUS;

EID: 33846498614     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0803     Document Type: Article

References (43)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A 2003 Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253
2. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones 3rd BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J 2003 Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2651-2662
3. Writing Group for the Women's Health Initiative 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
4. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M 2003 Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
5. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ 2003 Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289:2673-2684
6. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D 2003 Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2663-2672
7. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG 2003 Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348:1839-1854
8. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
9. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH 2004 Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291:2947-2958
10. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL 2003 Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 102:1225-1232
11. Delmas P, Bjarnason N, Mitlak B, Ravoux A-C, Shah A, Huster W, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
12. Love R, Mazess R, Barden H, Epstein S, Newcomb P, Jordan V, Carbone P, DeMets D 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
13. Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelsen T, Genant H, Christiansen C, Delmas P 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637-644
14. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, Norton L, Nichosen T, Bjarnason N, Morrow M, Lippman ME, Black D, Glusman J, Costa A, Jordan V 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 281:2189-2197
15. Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N 1998 Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388
16. Cranney A, Adachi JD 2005 Benefit-risk assessment of raloxifene in postmenopausal osteoporosis. Drug Saf 28:721-730
17. Chambon P 2005 The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 19:1418-1428
18. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA 2005 Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 26:465-478
19. Hewitt SC, Harrell JC, Korach KS 2005 Lessons in estrogen biology from knockout and transgenic animals. Annu Rev Physiol 67:285-308
20. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC 2004 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors α and β. Mol Biol Cell 15:1262-1272
21. Cvoro A, Tzagarakis-Foster C, Tatomer D, Paruthiyil S, Fox MS, Leitman DC 2006 Distinct roles of unliganded and liganded estrogen receptors in transcriptional repression. Mol Cell 21:555-564
22. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC 2001 Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 276:17808-17814
23. 2 cell cycle arrest. Cancer Res 64:423-428
24. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI 2005 The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 102:9802-9807
25. Choi I, Gudas LJ, Katzenellenbogen BS 2000 Regulation of keratin 19 gene expression by estrogen in human breast cancer cells and identification of the estrogen responsive gene region. Mol Cell Endocrinol 164:225-237
26. Parmar H, Young P, Emerman JT, Neve RM, Dairkee S, Cunha GR 2002 A novel method for growing human breast epithelium in vivo using mouse and human mammary fibroblasts. Endocrinology 143:4886-4896
27. Weitzmann MN, Pacifici R 2006 Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186-1194
28. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S 1998 Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112
29. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263
30. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852
31. Metivier R, Penot G, Hubner MR, Reid G, Brand H, Kos M, Gannon F 2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115:751-763
32. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
33. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F, Weisz A 1996 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12:2315-2324
34. Leygue E, Gol-Winkler R, Gompel A, Louis-Sylvestre C, Soquet L, Staub S, Kuttenn F, Mauvais-Jarvis P 1995 Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. J Steroid Biochem Mol Biol 52:299-305
35. Gustafsson JA, Warner M 2000 Estrogen receptor β in the breast: role in estrogen responsiveness and development of breast cancer. J Steroid Biochem Mol Biol 74:245-248
36. Mahady GB, Parrot J, Lee C, Yun GS, Dan A 2003 Botanical dietary supplement use in peri- and postmenopausal women. Menopause 10:65-72
37. Zava DT, Dollbaum CM, Blen M 1998 Estrogen and progestin bioactivity of foods, herbs, and spices. Proc Soc Exp Biol Med 217:369-378
38. Oerter Klein K, Janfaza M, Wong JA, Chang RJ 2003 Estrogen bioactivity in fo-ti and other herbs used for their estrogen-like effects as determined by a recombinant cell bioassay. J Clin Endocrinol Metab 88:4077-4079
39. Jackson RD, Wactawski-Wende J, Lacroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, Lewis CE, Beresford SA, Ko MG, Naughton MJ, Satterfield S, Bassford T 2006 Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative. J Bone Miner Res 21:817-828
40. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, Pettinger M, Heckbert SR, Greep N, Crawford S, Eaton CB, Kostis JB, Caralis P, Prentice R 2006 Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 166:357-365
41. An J, Ribeiro RC, Webb P, Gustafsson JA, Kushner PJ, Baxter JD, Leitman DC 1999 Estradiol repression of tumor necrosis factor-α transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 96:15161-15166
42. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith Jr JC 2003 Evaluation of an estrogen receptor-β agonist in animal models of human disease. Endocrinology 144:4241-4249
43. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, Mendelsohn ME 2001 Effects of estrogen on the vascular injury response in estrogen receptor α, β (double) knockout mice. Circ Res 89:534-539